Swift Biosciences develops next-generation sequencing (NGS) library preparation genomics kits for academic, translational, and clinical research. The acquisition complements IDT's existing portfolio of nucleic acid products for academic and commercial research, including pharmaceutical development and synthetic biology applications.

Swift associates and products will transition into IDT while continuing to operate from the company's existing facilities in Ann Arbor, MI.

IDT is an operating company within Danaher's Life Sciences platform. Financial terms of the transaction were not disclosed.

Swift Biosciences debuts new DNA library kit
Swift Biosciences has launched Swift 2S Sonic DNA library kit for low-cost enzymatic fragmentation-based library preparation. The kit is compatible with...

What Scientists Want from CRISPR Companies
Laboratories around the world are adopting the CRISPR/Cas9 genome editing technique for their research. Whether to engineer better cell lines for drug...